Key terms
About LTRN
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest LTRN news
Mar 20
2:02am ET
Lantern Pharma’s Triple Threat: Inflation, Global Tensions, and Pandemic Impacts Jeopardize Financial Health
Mar 19
6:29am ET
H.C. Wainwright Reaffirms Their Hold Rating on Lantern Pharma (LTRN)
Mar 18
4:25pm ET
Lantern Pharma Announces Fiscal Year and Q4 Results Webinar
Mar 18
4:07pm ET
Lantern Pharma reports Q4 EPS (39c), two estimates (40c)
Mar 15
8:04am ET
Lantern Pharma doses first two patients in LP-284 trial
Feb 15
8:19am ET
Lantern Pharma generates new class of ADCs with cryptophycin drug-payload
No recent news articles are available for LTRN
No recent press releases are available for LTRN
LTRN Financials
Key terms
Ad Feedback
LTRN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
LTRN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
